Emflaza FDA Approval History
FDA Approved: Yes (First approved February 9, 2017)
Brand name: Emflaza
Generic name: deflazacort
Dosage form: Tablets and Oral Suspension
Company: PTC Therapeutics, Inc.
Treatment for: Duchenne Muscular Dystrophy
Emflaza (deflazacort) is a glucocorticoid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Development timeline for Emflaza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.